IMvigor 210一线Atezolizumab治疗顺铂不合格转移性尿路上皮癌研究.pdfVIP

IMvigor210(Cohort1):First-line

AtezolizumabinCistin-

IneligibleMetastaticUrothelial

Carcinoma

CCOtConferenceCoverage*

ofthe2016ASCOAnnualMeeting,June3-7,2016

*CCOisantmedicaleducationcompanythatprovidesstate-of-the-artmedical

informationtohealthcareprofessionalsthroughconferencecoverageandothereducationalprograms.

ThisactivityissupportedbyeducationalgrantsfromAmgen,Ariad,

BayerHealthcarePharmaceuticals,CelgeneCorpora